Breaking Barriers in HIV Prevention: WHO's Latest PrEP Implementation Tool

The WHO's new PrEP implementation tool represents a major advancement in HIV prevention, offering a detailed guide for integrating PrEP into comprehensive prevention strategies. By addressing barriers, reducing stigma, and providing diverse PrEP options, the WHO aims to make HIV prevention more accessible and effective for all.

In a significant step towards global HIV prevention, the World Health Organization (WHO) has unveiled the "WHO Implementation Tool for Pre-exposure Prophylaxis (PrEP) of HIV Infection." This comprehensive guide aims to facilitate the implementation of oral and long-acting PrEP for diverse populations and settings, ensuring that HIV prevention strategies are more accessible, effective, and adaptable.

A New Approach to HIV Prevention

The WHO’s new PrEP implementation tool is the result of extensive collaboration among community organizations, healthcare providers, researchers, and other experts from around the world. The primary goal is to integrate PrEP into comprehensive HIV prevention strategies, thereby supporting PrEP uptake, persistence, and effective use. This aligns with the global goals set out in the Global Health Sector Strategies on HIV, viral hepatitis, and sexually transmitted infections for the period 2022–2030, as well as the global targets defined in the Political Declaration on HIV and AIDS adopted by the United Nations General Assembly in 2021.

Central to this approach is a commitment to a people-centered methodology, ensuring that services are not only accessible and available but also of high quality. The WHO emphasizes that PrEP should be integrated with other HIV prevention interventions, such as condom programming, voluntary medical male circumcision (VMMC), and harm reduction for people who use drugs.

Diverse PrEP Options for Different Needs

The implementation tool highlights three key PrEP products currently recommended by the WHO.

Oral PrEP containing Tenofovir Disoproxil Fumarate (TDF): This option has been proven highly effective when taken as directed, offering over 90% protection against HIV acquisition through sexual transmission.

Dapivirine Vaginal Ring (DVR): Recommended for women at substantial risk of HIV, the DVR provides a discreet, long-acting option for HIV prevention.

Long-acting Injectable Cabotegravir (CAB-LA): This is a new addition to the PrEP arsenal, offering a long-acting solution that requires less frequent dosing and has shown a 79% reduction in HIV acquisition risk compared to oral PrEP in clinical trials.

Each of these options provides different benefits, catering to individual preferences and circumstances, which is critical in making PrEP a more viable and appealing option for a wider range of people.

Implementing and Managing PrEP

Starting PrEP involves several steps to ensure safety and effectiveness. Providers need to identify clients who could benefit from PrEP, conduct HIV testing, assess for post-exposure prophylaxis (PEP), and address any contraindications. Clients should be given comprehensive information about PrEP choices and guided through the prescription and management process.

Follow-up is equally crucial. Regular HIV testing, discussions about adherence, managing side effects, and continued provision of PrEP drugs are necessary to maintain the effectiveness of PrEP. Special considerations are also needed for different populations and specific situations to ensure that everyone receives the care and support they need.

Overcoming Barriers and Reducing Stigma

A significant part of the WHO's strategy involves addressing the various barriers that prevent people from accessing PrEP. Legal and social challenges often hinder individuals from seeking PrEP, especially those from key populations who face additional stigma and discrimination.

Efforts must be made to create an environment where PrEP is promoted as a positive, responsible choice for sexual health. This includes normalizing PrEP use, reducing stigma, and ensuring that health services are both respectful and culturally competent.

Key Recommendations and Future Directions

The WHO has made several key recommendations over the years to enhance the effectiveness of PrEP,

2015: Oral PrEP should be offered as part of combination HIV prevention for those at substantial risk.

2021: DVR is recommended for women at substantial risk.

2022: CAB-LA is recommended for people at substantial risk.

The development of the implementation tool involved a thorough review of outdated guidance, identification of evidence gaps, and incorporation of the latest WHO recommendations and scientific evidence. This ensures that the tool is not only comprehensive but also relevant and up-to-date.

The intended use of this module is to provide practical support to a broad range of PrEP providers, including physicians, nurses, community health workers, pharmacists, and lay and peer providers. The guidance is designed to be adaptable to various settings, ensuring that PrEP services are user-centric and respectful of cultural differences.